Progressive Multifocal Leukoencephalopathy: Risk Factors, Management Strategies and Prognosis

Denise S. Coleman (Editor)

Series: Neurology – Laboratory and Clinical Research Developments
BISAC: MED056000



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



Progressive multifocal leukoencephalopathy (PML) is a rare, disabling and potentially fatal brain infection of the central nervous system (CNS) caused by reactivation of the John Cunningham virus (JCV). The most important risk factor for PML is immunosuppression associated with HIV/AIDS or therapy. Approximately 60 to 80% of the adult population has JC antibodies, but PML is rarely diagnosed. The chapters in this book include research on the pathologic features of PML, the diagnosis, risk factors, pathogenesis, and management strategies.
(Imprint: Nova Biomedical)


Chapter One
Progressive Multifocal Leukoencephalopathy: Current Concepts of a Renewed Disease
(Inês Correia, Lívia Sousa, Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal)

Chapter Two
Pathologic Features of Progressive Multifocal Leukoencephalopathy
(Erika E. Doxtader, Richard A. Prayson, Department of Pathology
Cleveland Clinic, Cleveland, OH, USA)

Chapter Three
Risk Factors and Treatment of Progressive Multifocal Leukoencephalopathy
(David Pérez-Callejo, Isabel Curto and Mariano Provencio, Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain)

Chapter Four
Progressive Multifocal Leukoencephalopathy: Risk Factors Related to Drugs and Management Strategies
(Ana Fernández Pérez, Santiago Piñeiro Conde, Pharmacy Service, University Hospital Lucus Augusti, Lugo, Spain)

Chapter Five
Risk of Immune Reconstitution Inflammatory Syndrome (IRIS) in Natalizumab-Associated PML
(Alberto Calvi, Milena Alessandra De Riz, Anna Pietroboni, Daniela Galimberti, Elio Scarpini, Neurology Unit, Dept. of Pathophysiology and Transplantation, University of Milan, Fondazione Ca’ Granda, IRCCS Ospedale Policlinico, Milan, Italy)


You have not viewed any product yet.